

# Bernard Escudier

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4610295/publications.pdf>

Version: 2024-02-01

41  
papers

11,124  
citations

361413

20  
h-index

289244

40  
g-index

42  
all docs

42  
docs citations

42  
times ranked

15955  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2015, 373, 1803-1813.	27.0	4,889
2	Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. <i>Science</i> , 2018, 359, 91-97.	12.6	3,689
3	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1370-1385.	10.7	594
4	Cross-reactivity between tumor MHC class II-restricted antigens and an enterococcal bacteriophage. <i>Science</i> , 2020, 369, 936-942.	12.6	217
5	Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. <i>European Urology</i> , 2017, 72, 368-376.	1.9	209
6	Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. <i>Cancer</i> , 2020, 126, 4156-4167.	4.1	201
7	Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients. <i>European Urology</i> , 2020, 78, 195-206.	1.9	192
8	Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. , 2020, 8, e000891.		160
9	Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status. <i>European Urology</i> , 2016, 70, 623-632.	1.9	115
10	Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. <i>European Journal of Cancer</i> , 2017, 87, 147-163.	2.8	108
11	Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. <i>Cancer</i> , 2022, 128, 2085-2097.	4.1	103
12	Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. <i>European Journal of Cancer</i> , 2019, 108, 33-40.	2.8	96
13	Tumor Growth Rate Provides Useful Information to Evaluate Sorafenib and Everolimus Treatment in Metastatic Renal Cell Carcinoma Patients: An Integrated Analysis of the TARGET and RECORD Phase 3 Trial Data. <i>European Urology</i> , 2014, 65, 713-720.	1.9	71
14	Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma. <i>Drugs</i> , 2018, 78, 1443-1457.	10.9	70
15	Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer. <i>Angiogenesis</i> , 2017, 20, 205-215.	7.2	59
16	Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma. <i>Drugs</i> , 2020, 80, 1169-1181.	10.9	53
17	Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial. <i>European Journal of Cancer</i> , 2020, 129, 107-116.	2.8	35
18	The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2019, 24, 338-348.	3.7	34

#	ARTICLE	IF	CITATIONS
19	Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6687-6695.	7.0	25
20	Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre. <i>European Journal of Cancer</i> , 2017, 79, 185-192.	2.8	24
21	Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: Analysis Using Diagnostic Nodes. <i>Oncologist</i> , 2015, 20, 1028-1035.	3.7	23
22	Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study. <i>European Journal of Cancer</i> , 2020, 136, 76-83.	2.8	19
23	Cabozantinib for the treatment of renal cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2499-2504.	1.8	18
24	Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study. <i>European Journal of Cancer</i> , 2017, 80, 55-62.	2.8	18
25	Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. <i>ESMO Open</i> , 2020, 5, e000852.	4.5	18
26	Response to systemic therapy in fumarate hydratase-deficient renal cell carcinoma. <i>European Journal of Cancer</i> , 2021, 151, 106-114.	2.8	18
27	Immune Checkpoint Inhibitors in Metastatic Clear-cell Renal Cell Carcinoma: Is PD-L1 Expression Useful?. <i>European Urology</i> , 2021, 79, 793-795.	1.9	10
28	Treating patients with renal cell carcinoma and bone metastases. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1135-1143.	2.4	9
29	NIVOREN GETUG-AFU 26 translational study: Association of PD-1, AXL, and PBRM-1 with outcomes in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N).. <i>Journal of Clinical Oncology</i> , 2020, 38, 618-618.	1.6	8
30	Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1081-e1088.	1.9	6
31	Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e595-e607.	1.9	5
32	A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation. <i>Angiogenesis</i> , 2019, 22, 383-395.	7.2	5
33	Sexual Disorders of Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Antiangiogenic Therapies. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 369-375.e1.	1.9	4
34	Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Étude des Tumeurs Uro-Génitales). <i>European Journal of Cancer</i> , 2021, 158, 1-11.	2.8	4
35	Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 488-494.	1.9	4
36	Towards rational post-nephrectomy follow-up guidelines in RCC. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 131-132.	27.6	3

#	ARTICLE	IF	CITATIONS
37	Sorafenibâ€“Sunitinib Sequence: The Jury Is Out. <i>European Urology</i> , 2015, 68, 848-849.	1.9	2
38	Therapeutic sequencing in the era of first-line immune checkpoint inhibitor combinations, a novel challenge in patients with metastatic clear-cell renal cell carcinoma. <i>Bulletin Du Cancer</i> , 2022, 109, 2S31-2S38.	1.6	2
39	Angiogenic and immunomodulatory biomarkers in axitinib-treated patients (pts) with advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 614-614.	1.6	1
40	Prospective observational study on pazopanib in patients treated for advanced/metastatic renal cell carcinoma (RCC): APOLON Study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 629-629.	1.6	1
41	Safety and efficacy of nivolumab in older patients (pts) with renal cell carcinoma: Results of a sub-group analysis of the GETUG-AFU 26 NIVOREN multicenter phase II study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 331-331.	1.6	0